Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura

EBioMedicine

Volumn 2, Issue 8, 2015, Pages 942-952

  Thomas, Mari R ^a,b   de Groot, Rens ^b   Scully, Marie A ^c   Crawley, James T B ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

ADAMTS13; Autoantibodies; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FOLLOW UP; HUMAN; IC50; IMMUNE RESPONSE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MICROTHROMBUS; MORTALITY; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; RELAPSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BLOOD; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; AUTOANTIBODIES; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84951573424     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.06.007     Document Type: Article

References (38)

1. Andersson H.M., Siegerink B., Luken B.M., Crawley J.T., Algra A., Lane D.A., et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012, 119(6):1555-1560. (Feb 9).
2. Chion C.K., Doggen C.J., Crawley J.T., Lane D.A., Rosendaal F.R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007, 109(5):1998-2000. (Mar 1).
3. Emlen W., Carl V., Burdick G. Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes. Clin. Exp. Immunol. 1992, 89(1):8-17. (Jul).
4. Ferrari S., Scheiflinger F., Rieger M., Mudde G., Wolf M., Coppo P., et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007, 109(7):2815-2822. (Apr 1).
5. Ferrari S., Mudde G.C., Rieger M., Veyradier A., Kremer Hovinga J.A., Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2009, 7(10):1703-1710. (Oct).
6. Ferrari S., Knobl P., Kolovratova V., Plaimauer B., Turecek P.L., Varadi K., et al. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2012, 10(1):156-158. (Jan).
7. Ferrari S., Palavra K., Gruber B., Kremer Hovinga J.A., Knobl P., Caron C., et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica 2014, 99(4):779-787. (Apr).
8. Feys H.B., Liu F., Dong N., Pareyn I., Vauterin S., Vandeputte N., et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J. Thromb. Haemost. 2006, 4(5):955-962. (May).
9. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98(6):1662-1666. (Sep 15).
10. Furlan M., Robles R., Morselli B., Sandoz P., Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 1999, 81(1):8-13. (Jan).
11. Gerritsen H.E., Turecek P.L., Schwarz H.P., Lammle B., Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb. Haemost. 1999, 82(5):1386-1389. (Nov).
12. Hovinga J.A., Vesely S.K., Terrell D.R., Lammle B., George J.N. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010, 115(8):1500-1511. (Feb 25, quiz 662).
13. Jian C., Xiao J., Gong L., Skipwith C.G., Jin S.Y., Kwaan H.C., et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012, 119(16):3836-3843. (Apr 19).
14. Johansson A., Erlandsson A., Eriksson D., Ullen A., Holm P., Sundstrom B.E., et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 2002, 94(4 Suppl):1306-1313. (Feb 15).
15. Klaus C., Plaimauer B., Studt J.D., Dorner F., Lammle B., Mannucci P.M., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004, 103(12):4514-4519. (Jun 15).
16. Kokame K., Nobe Y., Kokubo Y., Okayama A., Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J. Haematol. 2005, 129(1):93-100. (Apr).
17. Kosugi I., Muro H., Shirasawa H., Ito I. Endocytosis of soluble IgG immune complex and its transport to lysosomes in hepatic sinusoidal endothelial cells. J. Hepatol. 1992, 16(1-2):106-114. (Sep).
18. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494. (Oct 4).
19. Lotta L.A., Valsecchi C., Pontiggia S., Mancini I., Cannavo A., Artoni A., et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2014, 12(3):329-336.
20. Luken B.M., Turenhout E.A., Hulstein J.J., Van Mourik J.A., Fijnheer R., Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb. Haemost. 2005, 93(2):267-274. (Feb).
21. Luken B.M., Kaijen P.H., Turenhout E.A., Kremer Hovinga J.A., van Mourik J.A., Fijnheer R., et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2006, 4(11):2355-2364. (Nov).
22. Peyvandi F., Lavoretano S., Palla R., Feys H.B., Vanhoorelbeke K., Battaglioli T., et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008, 93(2):232-239. (Feb).
23. Pos W., Crawley J.T., Fijnheer R., Voorberg J., Lane D.A., Luken B.M. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010, 115(8):1640-1649. (Feb 25).
24. Pos W., Sorvillo N., Fijnheer R., Feys H.B., Kaijen P.H., Vidarsson G., et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 2011, 96(11):1670-1677. (Jun 28).
25. Rieger M., Ferrari S., Kremer Hovinga J.A., Konetschny C., Herzog A., Koller L., et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb. Haemost. 2006, 95(2):212-220. (Feb).
26. Schaller M., Vogel M., Kentouche K., Lammle B., Kremer Hovinga J.A. The spleen-derived autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 2014, 124(23):3469-3479. (Sep 26).
27. Scheiflinger F., Knobl P., Trattner B., Plaimauer B., Mohr G., Dockal M., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003, 102(9):3241-3243. (Nov 1).
28. Schifferli J.A., Taylor R.P. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989, 35(4):993-1003. (Apr).
29. Scully M., Cohen H., Cavenagh J., Benjamin S., Starke R., Killick S., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br. J. Haematol. 2007, 136(3):451-461. (Feb).
30. Scully M., McDonald V., Cavenagh J., Hunt B.J., Longair I., Cohen H., et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011, 118(7):1746-1753. (Aug 18).
31. Scully M., Hunt B.J., Benjamin S., Liesner R., Rose P., Peyvandi F., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br. J. Haematol. 2012, 25. (May).
32. Shelat S.G., Smith P., Ai J., Zheng X.L. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J. Thromb. Haemost. 2006, 4(8):1707-1717. (Aug).
33. Soejima K., Matsumoto M., Kokame K., Yagi H., Ishizashi H., Maeda H., et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003, 102(9):3232-3237. (Nov 1).
34. Vugmeyster Y., Xu X., Theil F.P., Khawli L.A., Leach M.W. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J. Biol. Chem. 2012, 3(4):73-92. (Apr 26).
35. Westwood J.P., Webster H., McGuckin S., McDonald V., Machin S.J., Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J. Thromb. Haemost. 2013, 11(3):481-490. (Mar).
36. Yang S., Jin M., Lin S., Cataland S., Wu H. ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. Haematologica 2011, 96(10):1521-1527. (Oct).
37. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus. Med. 2004, 14(1):39-44. (Feb).
38. Zheng X.L., Wu H.M., Shang D., Falls E., Skipwith C.G., Cataland S.R., et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010, 95(9):1555-1562. (Sep).